We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Atara Biotherapeutics (ATRA - Free Report) shares rallied 10% in the last trading session to close at $11.82. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 32.2% loss over the past four weeks.
The price rise can be attributed to growing investor optimism regarding Atara’s recent development related to its lead product candidate, tabelecleucel (tab-cel), a novel T-cell immunotherapy, which has been developed for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). The company’s resubmitted biologics license application for tab-cel is under priority review in the United States, and a decision from the FDA is due on Jan. 10, 2026.
This drug developer is expected to post quarterly loss of $0.83 per share in its upcoming report, which represents a year-over-year change of +71.7%. Revenues are expected to be $1.29 million, down 96.8% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Atara Biotherapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ATRA going forward to see if this recent jump can turn into more strength down the road.
Atara Biotherapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, CervoMed Inc. (CRVO - Free Report) , finished the last trading session 0.7% lower at $7.29. CRVO has returned -17.5% over the past month.
For CERVOMED INC, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.68. This represents a change of -23.6% from what the company reported a year ago. CERVOMED INC currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?
Atara Biotherapeutics (ATRA - Free Report) shares rallied 10% in the last trading session to close at $11.82. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 32.2% loss over the past four weeks.
The price rise can be attributed to growing investor optimism regarding Atara’s recent development related to its lead product candidate, tabelecleucel (tab-cel), a novel T-cell immunotherapy, which has been developed for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). The company’s resubmitted biologics license application for tab-cel is under priority review in the United States, and a decision from the FDA is due on Jan. 10, 2026.
This drug developer is expected to post quarterly loss of $0.83 per share in its upcoming report, which represents a year-over-year change of +71.7%. Revenues are expected to be $1.29 million, down 96.8% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Atara Biotherapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ATRA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Atara Biotherapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, CervoMed Inc. (CRVO - Free Report) , finished the last trading session 0.7% lower at $7.29. CRVO has returned -17.5% over the past month.
For CERVOMED INC, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.68. This represents a change of -23.6% from what the company reported a year ago. CERVOMED INC currently has a Zacks Rank of #3 (Hold).